MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, SNSE had -$1,995K decrease in cash & cash equivalents over the period. -$3,586K in free cash flow.

Cash Flow Overview

Change in Cash
-$1,995K
Free Cash flow
-$3,586K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-4,568 -11,800
Stock-based compensation expense
254 725
Depreciation and amortization
30 62
Accretion on marketable securities
-142 -442
Non-cash lease expense
366 770
Amortization of financing lease right-of-use assets
4 9
Loss on asset disposal
-1 -20
Prepaid expenses
-331 354
Other assets
126 -28
Accounts payable and accrued liabilities
269 -113
Compensation and employee benefits
381 -1,107
Operating lease liabilities
-386 -801
Other liabilities
0 -
Net cash used in operating activities
-3,586 -13,003
Purchases of property and equipment
0 16
Purchases of short-term investments
9,847 8,786
Maturities of short-term investments
11,590 24,500
Proceeds from sale of property and equipment
0 250
Net cash provided by investing activities
1,743 15,948
Principal payments for financing leases
152 525
Proceeds from the sale of financing lease assets
0 142
Payment of employee restricted stock tax withholdings
0 3
Employee stock purchase plan proceeds
0 5
Cash in lieu of fractional shares for reverse stock split
0 1
Net cash used in financing activities
-152 -382
Net increase in cash and cash equivalents
-1,995 2,563
Cash and cash equivalents at beginning of period
9,994 -
Cash and cash equivalents at end of period
10,562 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Sensei Biotherapeutics, Inc. (SNSE)

Sensei Biotherapeutics, Inc. (SNSE)